GlassScriptPhysician profile
Neil Theodore Smith
NPI 1104807981
$4,234.14
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $1,617 · 2021: $923.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $937.81 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $677.58 | 2019-2021 | |
| Lilly USA, LLC | $386.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $305.34 | 2019-2021 | |
| Pfizer INC. | $242.01 | 2019-2021 | |
| Glaxosmithkline, LLC. | $179.52 | 2019-2021 | |
| Amgen INC. | $172.76 | 2019-2021 | |
| Allergan, INC. | $107.20 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $90.39 | 2019-2021 | |
| Abbvie INC. | $86.22 | 2019-2021 | |
| Vivus LLC | $84.86 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $83.58 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $73.33 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $73.22 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $44.86 | 2019-2021 | |
| Astellas Pharma US INC | $44.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.41 | 2020-2021 | |
| Gilead Sciences, INC. | $38.09 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.36 | 2019 | |
| Amneal Pharmaceuticals LLC | $20.84 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.12 | 2019 | |
| Shire North American Group INC | $16.28 | 2019 | |
| Genentech USA, INC. | $15.73 | 2019 | |
| Alfasigma USA, INC. | $15.66 | 2021 | |
| Currax Pharmaceuticals LLC | $14.02 | 2019 | |
| Phadia US INC. | $12.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.